KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Current Deferred Revenue (2016 - 2019)

NovoCure (NVCR) has disclosed Current Deferred Revenue for 5 consecutive years, with $19.6 million as the latest value for Q4 2019.

  • Quarterly Current Deferred Revenue rose 4.32% to $19.6 million in Q4 2019 from the year-ago period, while the trailing twelve-month figure was $19.6 million through Dec 2019, up 4.32% year-over-year, with the annual reading at $19.6 million for FY2019, 4.32% up from the prior year.
  • Current Deferred Revenue hit $19.6 million in Q4 2019 for NovoCure, up from $18.8 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $19.6 million in Q4 2019 to a low of $52000.0 in Q4 2015.
  • Historically, Current Deferred Revenue has averaged $9.1 million across 5 years, with a median of $5.0 million in 2017.
  • Biggest five-year swings in Current Deferred Revenue: skyrocketed 4259.62% in 2016 and later increased 4.32% in 2019.
  • Year by year, Current Deferred Revenue stood at $52000.0 in 2015, then surged by 4259.62% to $2.3 million in 2016, then skyrocketed by 118.75% to $5.0 million in 2017, then surged by 278.48% to $18.8 million in 2018, then grew by 4.32% to $19.6 million in 2019.
  • Business Quant data shows Current Deferred Revenue for NVCR at $19.6 million in Q4 2019, $18.8 million in Q4 2018, and $5.0 million in Q4 2017.